Literature DB >> 9816290

Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells.

R Kumar1, M Mandal, A Lipton, H Harvey, C B Thompson.   

Abstract

Overexpression of HER2 in estrogen receptor (ER)-positive human breast tumors has been associated with resistance to endocrine therapy. Here we investigated the effects of HER2 on expression of apoptotic pathways and modulation of tamoxifen-induced apoptosis in ER-positive MCF-7 breast cancer cells. We report that HER2 overexpression in MCF-7 cells is accompanied by up-regulation of antiapoptotic Bcl-2 and Bcl-XL proteins and suppression of tamoxifen-induced apoptosis. In addition, human tumor cell lines that are both ER positive and overexpress HER2 also express enhanced levels of Bcl-2 compared to cells that are either ER positive or overexpress HER2 alone. Our findings suggest that possible deregulation of antiapoptotic Bcl-2 and Bcl-XL may be associated with the enhanced survival of HER2-overexpressing and ER-positive breast cancer cells treated with antiestrogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816290

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

1.  Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.

Authors:  Anatasha Crawford; Rita Nahta
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-09

Review 2.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-08       Impact factor: 4.292

3.  Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.

Authors:  Chel Hun Choi; Joon-Yong Chung; Jun Hyeok Kang; E Sun Paik; Yoo-Young Lee; Won Park; Sun-Ju Byeon; Eun Joo Chung; Byoung-Gie Kim; Stephen M Hewitt; Duk-Soo Bae
Journal:  Gynecol Oncol       Date:  2020-02-24       Impact factor: 5.482

4.  Regulation of Apoptosis by HER2 in Breast Cancer.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  J Carcinog Mutagen       Date:  2013-06-26

5.  Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.

Authors:  Norman C Peterson; Matthew D Servinsky; Archie Christian; Zhongsheng Peng; Weiping Qiu; Jill Mann; John Dicello; David L Huso
Journal:  Carcinogenesis       Date:  2005-04-28       Impact factor: 4.944

Review 6.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

7.  Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells.

Authors:  Anli Zhang; Hua Xue; Xiaoguang Ling; Yi Gao; Feng Yang; Liansheng Cheng; Jing Liu; Qiang Wu
Journal:  J Exp Clin Cancer Res       Date:  2010-03-10

8.  New developments in the treatment of HER2-positive breast cancer.

Authors:  Rita Nahta
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-05-01

9.  Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.

Authors:  Elizabeth S Henson; James B Johnston; Marek Los; Spencer B Gibson
Journal:  Biologics       Date:  2007-09

10.  Ginsenoside Rg3 Suppresses Palmitate-Induced Apoptosis in MIN6N8 Pancreatic beta-Cells.

Authors:  Kyong Kim; Min Park; Hye Young Kim
Journal:  J Clin Biochem Nutr       Date:  2009-12-29       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.